Cancer and Leukemia Group B - The Ohio State University

描述(由申请人提供)：这笔赠款的目的是通过为俄亥俄州立大学(OSU)的CALGB计划提供必要的基础设施，支持癌症和白血病B组(CALGB)的科学和临床活动。俄亥俄州立大学的多学科合作研究方法在为成人癌症提供更有效的预防、检测和治疗方法方面有着良好的记录，特别关注乳腺癌、胃肠道、泌尿生殖系统、血液和呼吸道恶性肿瘤。这项研究集中了内科、血液学、外科和放射肿瘤学家、移植医生、精神病学家、病理学家、细胞遗传学家、翻译和基础实验室科学家、统计学家、流行病学家、护士、药剂师和临床研究协调员的努力，这些研究设计和实施得很好，提出了相互关联的临床和基础科学问题，这些问题的答案对患者护理和减少高危人群中的癌症具有重要意义。该项目包括：1)在第一阶段、第二阶段和第三阶段临床试验中研究新的治疗药物及其毒性；2)评估新方案的疗效和毒性，包括新旧药物的组合，以努力更有效地利用协同组合；3)开发以最佳组合的手术、免疫和放射治疗措施解决特定肿瘤问题的多模式方法；4)相关的基础科学学科，如分子遗传学、生物化学、药理学、免疫学和生物统计学，参与特定治疗方案的设计和执行；5)通过使用这些方案教育博士后和博士后学生、护士、专职医务人员和医生来改善社区的癌症护理，6)评估与临床终点相关的生物学研究，以制定更合理的癌症管理，7)评估癌症控制努力，如早期发现，以及8)癌症的心理-社会方面的研究。在克拉拉·D·布卢姆菲尔德医学博士的全面协调下，OSU通过以下方式为CALGB的活动做出贡献：患者收益、研究方案的制定和领导、CALGB科学和行政委员会的领导和参与、多个CALGB核心实验室和设施的住房、CALGB会议的参与和集团出版物的作者身份。此外，俄亥俄州立大学进行机构试点，并提供实验室数据，以导致新的CALGB研究。对这项计划的支持将提高我们预防、检测、治疗和治愈成人癌症的能力，并改善癌症幸存者的生活质量。

DESCRIPTION (provided by applicant): The purpose of this grant is to support the scientific and clinical activities of Cancer and Leukemia Group B (CALGB) by providing necessary infrastructure to the CALGB program at The Ohio State University (OSU). The multi-disciplinary collaborative research approach at OSU has a track record of providing more effective methods of prevention, detection and treatment of adult cancer, with a particular focus on breast, gastrointestinal, genitourinary, hematologic, and respiratory malignancies. This research focuses the efforts of medical, hematologic, surgical and radiation oncologists, transplanters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators on well designed and conducted studies asking interrelated clinical and basic science questions whose answers contribute importantly to patient care and to reduction of cancer in populations at increased risk. This project includes the: 1) study of new therapeutic agents, and their toxicities, in Phase I, II and III clinical trials; 2) evaluation of efficacy and toxicity of new regimens including combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) development of multi-modal approaches to specific tumor problems using surgical, immunological and radiotherapeutic measures in optimal combinations; 4) involvement of pertinent basic science disciplines such as molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of specific therapy protocols; 5) improvement of cancer care in the community by using these protocols to educate pre- and post-doctoral students, nurses, allied medical personnel and physicians, 6) evaluation of biologic studies in correlation with clinical endpoints to develop more rationally based cancer management, 7) evaluation of cancer controls efforts such as early detection, and 8) study of the psycho-social aspects of cancer. Under the overall coordination of Clara D. Bloomfield, M.D., OSU contributes to CALGB activities through patient accrual to protocols, development and leadership of research protocols, leadership and participation in the scientific and administrative committees of CALGB, housing of multiple CALGB core labs and facilities, CALGB meeting participation and authorship on Group publications. In addition, OSU performs institutional pilots and provides lab data that lead to new CALGB studies. Support of this program should increase our ability to prevent, detect, treat and cure adult cancer and improve the quality of life of cancer survivors.